293 related articles for article (PubMed ID: 27344327)
21. Cardiovascular toxic effects of targeted cancer therapy.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Sep; 47(9):779-785. PubMed ID: 28531278
[TBL] [Abstract][Full Text] [Related]
22. [Cardiovascular complications of chemotherapy].
Tovena DM; Inzoli A; Donato G; Gazzaniga P; Bianchessi C
G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):165S-170S. PubMed ID: 23096398
[TBL] [Abstract][Full Text] [Related]
23. Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
Choueiri TK; Mayer EL; Je Y; Rosenberg JE; Nguyen PL; Azzi GR; Bellmunt J; Burstein HJ; Schutz FA
J Clin Oncol; 2011 Feb; 29(6):632-8. PubMed ID: 21205755
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular effects of systemic cancer treatment.
Senkus E; Jassem J
Cancer Treat Rev; 2011 Jun; 37(4):300-11. PubMed ID: 21126826
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
Ewer MS; Suter TM; Lenihan DJ; Niculescu L; Breazna A; Demetri GD; Motzer RJ
Eur J Cancer; 2014 Aug; 50(12):2162-70. PubMed ID: 24930624
[TBL] [Abstract][Full Text] [Related]
26. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy-induced cardiovascular toxicity: beyond anthracyclines.
Ai D; Banchs J; Owusu-Agyemang P; Cata JP
Minerva Anestesiol; 2014 May; 80(5):586-94. PubMed ID: 24122036
[TBL] [Abstract][Full Text] [Related]
28. Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: A systematic review and meta-analysis of genotypes effect.
Leong SL; Chaiyakunapruk N; Tassaneeyakul W; Arunmanakul P; Nathisuwan S; Lee SWH
Int J Cardiol; 2019 Apr; 280():190-197. PubMed ID: 30594345
[TBL] [Abstract][Full Text] [Related]
29. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Steingart RM; Bakris GL; Chen HX; Chen MH; Force T; Ivy SP; Leier CV; Liu G; Lenihan D; Lindenfeld J; Maitland ML; Remick SC; Tang WH
Am Heart J; 2012 Feb; 163(2):156-63. PubMed ID: 22305831
[TBL] [Abstract][Full Text] [Related]
30. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Wong MK; Jarkowski A
Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.
Abdel-Qadir H; Ethier JL; Lee DS; Thavendiranathan P; Amir E
Cancer Treat Rev; 2017 Feb; 53():120-127. PubMed ID: 28104567
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of dermatological toxicities associated with sorafenib.
Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
[TBL] [Abstract][Full Text] [Related]
33. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review.
Berardi R; Caramanti M; Savini A; Chiorrini S; Pierantoni C; Onofri A; Ballatore Z; De Lisa M; Mazzanti P; Cascinu S
Crit Rev Oncol Hematol; 2013 Oct; 88(1):75-86. PubMed ID: 23522920
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials.
Kang S; Yang Y; Li CJ; Gao R
Clin Ther; 2007 Nov; 29(11):2406-18. PubMed ID: 18158081
[TBL] [Abstract][Full Text] [Related]
36. Sudden cardiovascular death following myocardial infarction: the importance of left ventricular systolic dysfunction and congestive heart failure.
Abildstrom SZ; Ottesen MM; Rask-Madsen C; Andersen PK; Rosthøj S; Torp-Pedersen C; Køber L
Int J Cardiol; 2005 Sep; 104(2):184-9. PubMed ID: 16168812
[TBL] [Abstract][Full Text] [Related]
37. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
[TBL] [Abstract][Full Text] [Related]
38. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Zhou JX; Feng LJ; Zhang X
Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
[TBL] [Abstract][Full Text] [Related]
39. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
[TBL] [Abstract][Full Text] [Related]
40. Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety.
Yardley DA
Clin Breast Cancer; 2010 Apr; 10(2):119-29. PubMed ID: 20353933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]